DESIRNA

Design of Novel Polyelectrolyte Multilayer Based Delivery Systems for Therapeutic Antibodies and siRNA

Coordinatore	more  Organization address address: PASEO MIRAMON PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C 182 city: SAN SEBASTIAN postcode: 20009 contact info Titolo: Dr. Nome: Sergio Enrique Cognome: Moya Email: send email Telefono: 34943005311 Fax: 34943005301
Nazionalità Coordinatore	Non specificata
Totale costo	672˙519 €
EC contributo	0 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-06-01   -   2014-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES  Organization address address: PASEO MIRAMON PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C 182 city: SAN SEBASTIAN postcode: 20009 contact info Titolo: Dr. Nome: Sergio Enrique Cognome: Moya Email: send email Telefono: 34943005311 Fax: 34943005301	ES (SAN SEBASTIAN)	coordinator	173˙606.00
2	Capsulution Pharma AG  Organization address address: VOLMERSTRASSE 7B city: Berlin postcode: 12489 contact info Titolo: Mr. Nome: Alexander Cognome: Herrmann Email: send email Telefono: 49306700000000 Fax: 49306700000000	DE (Berlin)	participant	340˙518.00
3	UNIVERSITAET LEIPZIG  Organization address address: RITTERSTRASSE 26 city: LEIPZIG postcode: 4109 contact info Titolo: Prof. Nome: Edwin Cognome: Donath Email: send email Telefono: 493420000000 Fax: 493420000000	DE (LEIPZIG)	participant	158˙395.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The design and fabrication of biocompatible carrier systems for RNA based medicine and therapeutic antibodies equipped with multiple functions suitable for controlled and targeted delivery is the main scope of this proposal. General strategies for the encapsulation and release of RNA and proteins will be developed on the basis of the Layer by Layer technique (LBL) employing core materials tailored to the physico-chemical properties of the respective medications. Alternatively, RNA and antibodies can be also assembled between polyelectrolyte layers. The multilayers will progressive degrade in extracellular media or after being uptake in cells. The progressive degradation of the multilayer will provide a sustainable delivery of the therapeutic agent. The LBL provides also the means to modify the surface of the carrier to increase circulation or to increase specific uptake, according to the intended therapeutic action. To fulfil this aim biocompatible lipid layers will be engineered onto the surface of the carriers. This lipid coat is furthermore the matrix for the incorporation of targeting functions. The encapsulation of therapeutic antibodies, besides its very general importance, specifically addresses ocular applications, to meet urgent delivery problems. The design of a RNA carriers intended for silencing specific genes addresses a rather challenging problem of delivery. Its solution may help to pave the way for the application of the powerful RNA tools as therapeutic agents. The processing and distribution, in vitro and in vivo, of these carriers will be intensively studied. A comprehensive knowledge of how these processes take place will be paramount for the improvement of the coatings and to enhance their performance. Cyitotoxicity of carriers will also be studied.'